Accession Number : ADA318583

Title :   Utilization of an NCI Infrastructure to Evaluate Breast Cancer Patient Outcomes of Importance in Determining Priorities for New Health Care Reform.

Descriptive Note : Annual rept. 1 Aug 95-31 Jul 96,

Corporate Author : CALIFORNIA UNIV SAN FRANCISCO

Personal Author(s) : Smith, Garrett A. ; Henderson, I. C.

PDF Url : ADA318583

Report Date : AUG 1996

Pagination or Media Count : 16

Abstract : This project continues to develop and refine a novel clinical curriculum that utilizes resources from diverse disciplines. I have combined subspecialty training in oncology with formal courses in biostatistics, epidemiology, and health policy research, in order to develop expertise in clinical trials methodology and health care reform. The Clinical Research Scholars Program served as a foundation in outcomes research during the first year of the project, the second year of the project focused on an in depth analysis of highdose chemotherapy with peripheral blood stem cell transplant as a treatment for breast cancer. Specifically, outcomes research methodology highlighted a comprehensive review of HDC for breast cancer, and compared this technology to other new treatments for breast cancer. Technology assessment serves a vital role in the design of clinical pathways in an expanding managed care marketplace. Specific evidence-based guidelines were generated in an attempt to clarify the controversy surrounding the investigational nature of HDC, and explore the impact of this new technology on practice patterns and 3rd-party payers coverage. During the final phase of the training grant, a new outpatient highdose chemotherapy program will be implemented at the University of California, San Francisco with particular emphasis on quality-of life and cost-benefit analysis. The goal is to incorporate outcomes assessment into a Managed Care marketplace.

Descriptors :   *PATIENTS, *BREAST CANCER, METHODOLOGY, MANAGEMENT, TRAINING, COST ANALYSIS, HEALTH, CLINICAL MEDICINE, MEDICAL SERVICES, INSURANCE, BENEFITS, EPIDEMIOLOGY, PHARMACOLOGY, CHEMOTHERAPY, BLOOD CELLS.

Subject Categories : Administration and Management
      Economics and Cost Analysis
      Medicine and Medical Research
      Pharmacology

Distribution Statement : APPROVED FOR PUBLIC RELEASE